Primary Human Immune Response to Neisseria meningitidis Serogroup C in Interleukin-12--Treated Severe Combined Immunodeficient Mice Engrafted with Human Peripheral Blood Lymphocytes
Lack of primary immune response in severe combined immunodeficient (SCID) mice engrafted with human peripheral blood lymphocytes (hu-PBL) has limited the applicability of this model. Use of human cytokines, in particular interleukin (IL)-12, was studied in the hu-PBL–SCID model. SCID mice were treated with IL-12 and reconstituted with hu-PBL in T replacement factor. The hu-PBL–SCID mice were immunized with serogroup C meningococcal polysaccharide (MCPS). The MCPS-specific antibody response was determined by ELISA. Thirteen of the 15 immunized, IL-12-treated hu-PBL–SCID mice demonstrated a primary human antibody response to MCPS ranging from 0.25 to 3.3 µg/mL, while no MCPS-specific antibody response was detectable in the 18 controls. Expression of cross-reactive idiotypic markers found on human anti-MCPS antibodies in the immunized hu-PBL–SCID mice was similar to that observed in immunized volunteers.